19192-Lung Cancer-NSCLC-547

Lung Cancer

A PHASE III, RANDOMIZED, DOUBLE-BLINDED, PLACEBO-CONTROLLED STUDY OF TIRAGOLUMAB, AN ANTI-TIGIT ANTIBODY,IN COMBINATION WITH ATEZOLIZUMAB COMPARED WITH PLACEBO IN COMBINATION WITH ATEZOLIZUMAB IN PATIENTS WITH PREVIOUSLY UNTREATED LOCALLY ADVANCED UNRESECTABLE OR METASTATIC PD-L1-SELECTED NON-SMALL CELL LUNG CANCER (GO41717)

  • Details

ClinicalTrials.gov ID: NCT04294810
Diagnosis Type: NSCLC
USOR Number:

  • Address

310 Smith Ave N
Suite 100
Saint Paul, MN 55102
P: (651) 251-5500

Search by practice name, trial titles, indicators and specific disease types.